Get started
Award

Su2c-aacr-dt1012)

Funded outputs count: 21
Funder award ID: SU2C-AACR-DT1012)
OpenAlex ID: G1663198200
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2023 · Samuel Rosner, Joshua E. Reuss, et al. · Clinical Cancer Research · 74
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
2020 · Catherine S. Grasso, Jennifer Tsoi, et al. · Cancer Cell · 54
PDF
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
2020 · Joshua E Reuss, Valsamo Anagnostou, et al. · Journal for ImmunoTherapy of Cancer · 165
PDF
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
2019 · Jiajia Zhang, Zhicheng Ji, et al. · Clinical Cancer Research · 153
PDF
Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors
2019 · Nicolas J. Llosa, Brandon Luber, et al. · Clinical Cancer Research · 67
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
2019 · Kellie N. Smith, Nicolas J. Llosa, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
2019 · Kellie N. Smith, Nicolas J. Llosa, et al. · Journal for ImmunoTherapy of Cancer · 45
PDF
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
2018 · Patrick M. Forde, Jamie E. Chaft, et al. · New England Journal of Medicine · 2,096
PDF
PD-L1 expression in inflammatory myofibroblastic tumors
2018 · Tricia R Cottrell, Anh T Duong, et al. · Modern Pathology · 31
PDF
A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
2018 · Jing Zhou, Michael T. Bethune, et al. · PLoS ONE · 15
PDF
Implications of the tumor immune microenvironment for staging and therapeutics
2017 · Janis M Taube, Jérôme Galon, et al. · Modern Pathology · 359
PDF
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
2017 · Genevieve J Kaunitz, Tricia R Cottrell, et al. · Laboratory Investigation · 212
PDF
Novel immunotherapy clinical trials in malignant pleural mesothelioma
2017 · Zachary E. Tano, Navin K. Chintala, et al. · Annals of Translational Medicine · 8
PDF
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017 · Angel Garcia-Diaz, Daniel Sanghoon Shin, et al. · Cell Reports · 1,934
PDF
CAR T‐cell therapy for pancreatic cancer
2017 · Carl J. DeSelm, Zachary E. Tano, et al. · Journal of Surgical Oncology · 112
What does PD-L1 positive or negative mean?
2016 · Antoni Ribas, Siwen Hu-Lieskovan · The Journal of Experimental Medicine · 335
PDF
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
2016 · Ludmila Danilova, Hao Wang, et al. · Proceedings of the National Academy of Sciences · 161
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
2016 · Leonid Cherkassky, Aurore Morello, et al. · Journal of Clinical Investigation · 1,075
PDF
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
2016 · Jesse M. Zaretsky, Angel Garcia-Diaz, et al. · New England Journal of Medicine · 3,222
PDF
Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
2016 · Aude G. Chapuis, Sylvia M. Lee, et al. · The Journal of Experimental Medicine · 86
PDF
PD-1 blockade induces responses by inhibiting adaptive immune resistance
2014 · Paul C. Tumeh, Christina L. Harview, et al. · Nature · 6,587
PDF
Year
Topic